tiprankstipranks
Trending News
More News >
Health Catalyst (HCAT)
NASDAQ:HCAT
US Market
Advertisement

Health Catalyst (HCAT) Stock Forecast & Price Target

Compare
450 Followers
See the Price Targets and Ratings of:

HCAT Analyst Ratings

Moderate Buy
10Ratings
Moderate Buy
3 Buy
7 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Health
Catalyst
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

HCAT Stock 12 Month Forecast

Average Price Target

$4.31
▲(30.61% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Health Catalyst in the last 3 months. The average price target is $4.31 with a high forecast of $6.00 and a low forecast of $3.50. The average price target represents a 30.61% change from the last price of $3.30.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","4":"$4","6":"$6","8":"$8","10":"$10"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.31</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,4,6,8,10],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.4,3.6,3.8,4,4.2,4.4,4.6,4.8,5,5.2,5.4,5.6,5.800000000000001,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.4,3.4699999999999998,3.54,3.61,3.6799999999999997,3.75,3.82,3.8899999999999997,3.96,4.029999999999999,4.1,4.17,4.239999999999999,{"y":4.31,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.4,3.4076923076923076,3.4153846153846152,3.423076923076923,3.4307692307692306,3.4384615384615382,3.446153846153846,3.453846153846154,3.4615384615384617,3.4692307692307693,3.476923076923077,3.4846153846153847,3.4923076923076923,{"y":3.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.19,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.05,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.7,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.02,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.63,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.67,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.33,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.79,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.05,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$6.00Average Price Target$4.31Lowest Price Target$3.50
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BTIG
Hold
Reiterated
09/05/25
Cautious Hold Rating on Health Catalyst Amid Regulatory and Transition Challenges
TR | OpenAI - 4o Analyst forecast on HCAT
TR | OpenAI - 4o
TR | OpenAI - 4o
$3.5
Hold
6.06%
Upside
Reiterated
09/03/25
AI Generated ArticleAI Generated Article
William Blair Analyst forecast on HCAT
William Blair
William Blair
Buy
Reiterated
09/02/25
Health Catalyst: Strong Buy Rating Amidst Long-Term Growth Prospects and Industry LeadershipWe recently attended the three-day 2025 (HAS 25) in Utah—the annual client and user group conference hosted by Health Catalyst. The event was well attended, in our view, with attendees representing a diverse mix of data and analytics professionals, clinicians, and health system executives.
Canaccord Genuity Analyst forecast on HCAT
Canaccord Genuity
Canaccord Genuity
$9$5
Buy
51.52%
Upside
Reiterated
08/29/25
Health Catalyst price target lowered to $5 from $9 at CanaccordHealth Catalyst price target lowered to $5 from $9 at Canaccord
Evercore ISI
$3$4
Hold
21.21%
Upside
Reiterated
08/28/25
Evercore ISI Sticks to Their Hold Rating for Health Catalyst (HCAT)
Piper Sandler Analyst forecast on HCAT
Piper Sandler
Piper Sandler
$8$4
Hold
21.21%
Upside
Downgraded
08/27/25
Health Catalyst downgraded to Neutral from Overweight at Piper SandlerHealth Catalyst downgraded to Neutral from Overweight at Piper Sandler
Wells Fargo Analyst forecast on HCAT
Wells Fargo
Wells Fargo
$10$6
Buy
81.82%
Upside
Reiterated
08/11/25
Health Catalyst's Strategic Restructuring and Cost Management Justify Buy Rating Despite Revenue Guidance Reduction
Stifel Nicolaus Analyst forecast on HCAT
Stifel Nicolaus
Stifel Nicolaus
$5.5$4.5
Hold
36.36%
Upside
Reiterated
08/08/25
Stifel Nicolaus Sticks to Their Hold Rating for Health Catalyst (HCAT)
Citi
$6.5$3.5
Hold
6.06%
Upside
Downgraded
08/08/25
Health Catalyst downgraded to Neutral from Buy at CitiHealth Catalyst downgraded to Neutral from Buy at Citi
Cantor Fitzgerald Analyst forecast on HCAT
Cantor Fitzgerald
Cantor Fitzgerald
$9$4
Hold
21.21%
Upside
Downgraded
08/07/25
Health Catalyst downgraded to Neutral from Overweight at Cantor FitzgeraldHealth Catalyst downgraded to Neutral from Overweight at Cantor Fitzgerald
J.P. Morgan Analyst forecast on HCAT
J.P. Morgan
J.P. Morgan
$9
Buy
172.73%
Upside
Reiterated
05/20/25
Health Catalyst (HCAT) Receives a Buy from J.P. Morgan
KeyBanc
$7$5
Buy
51.52%
Upside
Reiterated
04/16/25
KeyBanc Remains a Buy on Health Catalyst (HCAT)
Stephens
$7$5
Hold
51.52%
Upside
Reiterated
03/06/25
Health Catalyst price target lowered to $5 from $7 at StephensHealth Catalyst price target lowered to $5 from $7 at Stephens
RBC Capital Analyst forecast on HCAT
RBC Capital
RBC Capital
$7$6
Hold
81.82%
Upside
Reiterated
02/26/25
Health Catalyst (HCAT) Receives a Hold from RBC Capital
Barclays
$14
Buy
324.24%
Upside
Reiterated
11/07/24
Barclays Sticks to Their Buy Rating for Health Catalyst (HCAT)
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
BTIG
Hold
Reiterated
09/05/25
Cautious Hold Rating on Health Catalyst Amid Regulatory and Transition Challenges
TR | OpenAI - 4o Analyst forecast on HCAT
TR | OpenAI - 4o
TR | OpenAI - 4o
$3.5
Hold
6.06%
Upside
Reiterated
09/03/25
AI Generated ArticleAI Generated Article
William Blair Analyst forecast on HCAT
William Blair
William Blair
Buy
Reiterated
09/02/25
Health Catalyst: Strong Buy Rating Amidst Long-Term Growth Prospects and Industry LeadershipWe recently attended the three-day 2025 (HAS 25) in Utah—the annual client and user group conference hosted by Health Catalyst. The event was well attended, in our view, with attendees representing a diverse mix of data and analytics professionals, clinicians, and health system executives.
Canaccord Genuity Analyst forecast on HCAT
Canaccord Genuity
Canaccord Genuity
$9$5
Buy
51.52%
Upside
Reiterated
08/29/25
Health Catalyst price target lowered to $5 from $9 at CanaccordHealth Catalyst price target lowered to $5 from $9 at Canaccord
Evercore ISI
$3$4
Hold
21.21%
Upside
Reiterated
08/28/25
Evercore ISI Sticks to Their Hold Rating for Health Catalyst (HCAT)
Piper Sandler Analyst forecast on HCAT
Piper Sandler
Piper Sandler
$8$4
Hold
21.21%
Upside
Downgraded
08/27/25
Health Catalyst downgraded to Neutral from Overweight at Piper SandlerHealth Catalyst downgraded to Neutral from Overweight at Piper Sandler
Wells Fargo Analyst forecast on HCAT
Wells Fargo
Wells Fargo
$10$6
Buy
81.82%
Upside
Reiterated
08/11/25
Health Catalyst's Strategic Restructuring and Cost Management Justify Buy Rating Despite Revenue Guidance Reduction
Stifel Nicolaus Analyst forecast on HCAT
Stifel Nicolaus
Stifel Nicolaus
$5.5$4.5
Hold
36.36%
Upside
Reiterated
08/08/25
Stifel Nicolaus Sticks to Their Hold Rating for Health Catalyst (HCAT)
Citi
$6.5$3.5
Hold
6.06%
Upside
Downgraded
08/08/25
Health Catalyst downgraded to Neutral from Buy at CitiHealth Catalyst downgraded to Neutral from Buy at Citi
Cantor Fitzgerald Analyst forecast on HCAT
Cantor Fitzgerald
Cantor Fitzgerald
$9$4
Hold
21.21%
Upside
Downgraded
08/07/25
Health Catalyst downgraded to Neutral from Overweight at Cantor FitzgeraldHealth Catalyst downgraded to Neutral from Overweight at Cantor Fitzgerald
J.P. Morgan Analyst forecast on HCAT
J.P. Morgan
J.P. Morgan
$9
Buy
172.73%
Upside
Reiterated
05/20/25
Health Catalyst (HCAT) Receives a Buy from J.P. Morgan
KeyBanc
$7$5
Buy
51.52%
Upside
Reiterated
04/16/25
KeyBanc Remains a Buy on Health Catalyst (HCAT)
Stephens
$7$5
Hold
51.52%
Upside
Reiterated
03/06/25
Health Catalyst price target lowered to $5 from $7 at StephensHealth Catalyst price target lowered to $5 from $7 at Stephens
RBC Capital Analyst forecast on HCAT
RBC Capital
RBC Capital
$7$6
Hold
81.82%
Upside
Reiterated
02/26/25
Health Catalyst (HCAT) Receives a Hold from RBC Capital
Barclays
$14
Buy
324.24%
Upside
Reiterated
11/07/24
Barclays Sticks to Their Buy Rating for Health Catalyst (HCAT)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Health Catalyst

1 Month
xxx
Success Rate
13/24 ratings generated profit
54%
Average Return
+1.97%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 54.17% of your transactions generating a profit, with an average return of +1.97% per trade.
3 Months
xxx
Success Rate
12/24 ratings generated profit
50%
Average Return
+3.31%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +3.31% per trade.
1 Year
Richard CloseCanaccord Genuity
Success Rate
6/24 ratings generated profit
25%
Average Return
-21.72%
reiterated a buy rating 9 days ago
Copying Richard Close's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -21.72% per trade.
2 Years
xxx
Success Rate
3/24 ratings generated profit
13%
Average Return
-47.80%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 12.50% of your transactions generating a profit, with an average return of -47.80% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HCAT Analyst Recommendation Trends

Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
8
6
6
3
3
Buy
4
2
1
2
3
Hold
11
14
19
25
22
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
23
22
26
30
28
In the current month, HCAT has received 6 Buy Ratings, 22 Hold Ratings, and 0 Sell Ratings. HCAT average Analyst price target in the past 3 months is 4.31.
Each month's total comprises the sum of three months' worth of ratings.

HCAT Financial Forecast

HCAT Earnings Forecast

Next quarter’s earnings estimate for HCAT is $0.06 with a range of $0.03 to $0.09. The previous quarter’s EPS was $0.04. HCAT beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 32.86% of the time in the same period. In the last calendar year HCAT has Outperformed its overall industry.
Next quarter’s earnings estimate for HCAT is $0.06 with a range of $0.03 to $0.09. The previous quarter’s EPS was $0.04. HCAT beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 32.86% of the time in the same period. In the last calendar year HCAT has Outperformed its overall industry.

HCAT Sales Forecast

Next quarter’s sales forecast for HCAT is $76.80M with a range of $74.91M to $85.00M. The previous quarter’s sales results were $80.72M. HCAT beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 50.00% of the time in the same period. In the last calendar year HCAT has Outperformed its overall industry.
Next quarter’s sales forecast for HCAT is $76.80M with a range of $74.91M to $85.00M. The previous quarter’s sales results were $80.72M. HCAT beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 50.00% of the time in the same period. In the last calendar year HCAT has Outperformed its overall industry.

HCAT Stock Forecast FAQ

What is HCAT’s average 12-month price target, according to analysts?
Based on analyst ratings, Health Catalyst’s 12-month average price target is 4.31.
    What is HCAT’s upside potential, based on the analysts’ average price target?
    Health Catalyst has 30.61% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is HCAT a Buy, Sell or Hold?
          Health Catalyst has a consensus rating of Moderate Buy which is based on 3 buy ratings, 7 hold ratings and 0 sell ratings.
            What is Health Catalyst’s price target?
            The average price target for Health Catalyst is 4.31. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $6.00 ,the lowest forecast is $3.50. The average price target represents 30.61% Increase from the current price of $3.3.
              What do analysts say about Health Catalyst?
              Health Catalyst’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of HCAT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis